Illustrative image.

Hyrimoz

Name: Hyrimoz
Brand: Sandoz
Availability: InStock

Adalimumab-adaz

Prescription required

$2976.00

40mg/0.8ml · 3 × 2 pen · 3 months supply

BrandBranded medicine· By Sandoz

$992.00 per month

Strength

How long a supply?

1 month$992.00 a monthOne-off$992.00

3 months$992.00 a monthOne-off$2976.00

6 months$992.00 a monthOne-off$5952.00

Supplied from Israel

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Annual cost

$12896a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

40mg/0.8ml

40mg

FDA boxed warningSerious infections and malignancy

SERIOUS INFECTIONS

Discontinue HYRIMOZ if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HYRIMOZ use and during therapy. Initiate treatment for latent TB prior to HYRIMOZ use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with HYRIMOZ prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HYRIMOZ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

MALIGNANCY

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.

Perform test for latent TB; if positive, start treatment for TB prior to starting HYRIMOZ.

Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

Read this with the rest of the clinical information

About Hyrimoz

Overview

Hyrimoz contains adalimumab-adaz, a TNF-blocking medicine supplied as a prefilled pen or syringe for injection under the skin. It treats several inflammatory conditions, including moderately to severely active rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis in adults. Other uses include certain forms of juvenile idiopathic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and non-infectious uveitis, with eligibility depending on the condition, age and severity. It works by blocking TNF-alpha, a protein involved in inflammation and normal immune responses.

What it treats

• Moderately to severely active rheumatoid arthritis in adults. • Moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older. • Active psoriatic arthritis in adults. • Active ankylosing spondylitis in adults. • Moderately to severely active Crohn’s disease in patients aged 6 years and older. • Moderately to severely active ulcerative colitis in adults. Effectiveness has not been established in patients who have lost response to or could not tolerate TNF blockers. • Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, when other systemic therapies are medically less appropriate. • Moderate to severe hidradenitis suppurativa in patients aged 12 years and older. • Non-infectious intermediate, posterior and panuveitis in patients aged 2 years and older.

Safety information

Side effects

Common side effects include upper respiratory infections, sinus infections, headache, rash, and reactions where the injection is given, such as redness, itching, bleeding, pain or swelling. Other reported side effects include nausea, abdominal pain, back pain and urinary tract infections. Contact a doctor promptly if you develop an infection. Serious infections, including tuberculosis and invasive fungal infections, have occurred, and some have been fatal. Hyrimoz should not be started during an active infection and must be stopped if an infection becomes serious. Serious allergic reactions, including anaphylaxis, can occur and require immediate medical attention. Seek immediate medical attention if symptoms of reduced blood cell counts develop. Other serious risks to discuss with your doctor include cancer, reactivation of hepatitis B, new or worsening nerve disorders involving damage to the protective covering of nerves, new or worsening heart failure, lupus-like illness and autoimmune hepatitis. Cancer occurred more often in adalimumab-treated patients than in control groups. People who carry hepatitis B need monitoring during treatment and for several months afterwards. Raised liver enzymes have also been reported; severe liver reactions, including acute liver failure, have occurred with TNF-blocking medicines.

FDA boxed warning

Serious infections and malignancy

SERIOUS INFECTIONS

Discontinue HYRIMOZ if a patient develops a serious infection or sepsis.

Reported infections include:

Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria.

Carefully consider the risks and benefits of treatment with HYRIMOZ prior to initiating therapy in patients with chronic or recurrent infection.

MALIGNANCY

Perform test for latent TB; if positive, start treatment for TB prior to starting HYRIMOZ.

Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

When to call your doctor

• Seek immediate medical attention for chest pain or difficulty breathing. • Seek immediate medical attention for fainting, confusion, or a fast or irregular heartbeat. • Seek immediate medical attention for blood in your urine or bleeding from your stomach or bowel.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The FDA label lists no formal contraindications for Hyrimoz. However, treatment should not be started during an active infection. If an infection develops, careful monitoring is needed, and Hyrimoz should be stopped if the infection becomes serious. Conditions requiring caution include: • Hepatitis B infection: carriers need monitoring during treatment and for several months afterward. If the virus reactivates, Hyrimoz should be stopped and antiviral treatment started. • Demyelinating disease: new disease or worsening of existing disease may occur. • Heart failure: new or worsening heart failure may occur. • Low blood cell counts: seek immediate medical attention if symptoms develop; stopping treatment may be considered. Serious allergic reactions, including anaphylaxis, may occur. Malignancies occurred more often in patients treated with adalimumab than in control groups. Serious fungal infections should be considered if a widespread illness develops, particularly in people who live in or travel to areas where these infections are common. Hyrimoz should be stopped if a lupus-like syndrome or autoimmune hepatitis develops.

Interactions

Using Hyrimoz with abatacept or anakinra increases the risk of serious infection. Tell your doctor if you take either medicine. Avoid live vaccines while using Hyrimoz, and check with your doctor before receiving one.

Using Hyrimoz

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton to protect it from light. Check the pack for whether it must be refrigerated before first use and how long it may be kept at room temperature afterwards. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label HYRIMOZ (ADALIMUMAB-ADAZ) INJECTION, SOLUTION HYRIMOZ (ADALIMUMAB-ADAZ) KIT [SANDOZ INC] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.